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Summary We aimed to detect antibodies against Crimean-Congo hemorrhagic fever virus
(CCHFV) in healthcare workers (HCWs) in an endemic region. The study was conducted in a
tertiary care hospital that had cared for CCHFV infected patients in the period 2002—2003. The
sera from the HCWs were collected one month after the last admitted hospital case (October
2003), and sent to the Pasteur Institute, Lyon, France to be studied for CCHF IgM and IgG by ELISA.
The total number of HCWs included in the study was 75; the median age was 30, 68% of the
subjects were female, and 83% of the HCWs were at risk of exposure to the body fluids of patients.
Only one HCW from the group without risk of exposure was CCHF IgG positive. The adherence rate
to universal precautions was high. In conclusion, a lack of CCHFV transmission from patients to
HCWs was observed. This result could be related to the high rate of compliance to the universal
precautions, which are sufficient to protect against CCHFV infection.
# 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.Introduction
Crimean-Congo hemorrhagic fever (CCHF) is a fatal viral
infection occurring in parts of Africa, Asia, Eastern Europe,
the Balkans, and the Middle East.1—3 The Crimean-Congo
hemorrhagic fever virus (CCHFV) belongs to the genus
Nairovirus in the Bunyaviridae family and causes severe
disease in humans, with a reported mortality rate of 15—
30%.4 It is also classified as one of the potential agents
of bioterrorism. Humans become infected mostly through tick* Corresponding author. Tel.: +90 312 4194227.
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doi:10.1016/j.ijid.2005.10.009bites, ordirect contactwithbloodfluidsor tissues fromviremic
patients or viremic livestock.5,6 The disease has caused noso-
comial outbreaks with high mortality, and percutaneous
exposure has been shown to have the highest risk of transmis-
sion.3,7—12 Documented exposure in these instances was direct
contact with viremic blood from CCHFV-infected patients
through accidental needlestick injuries.11—14 The risks asso-
ciated with various other modes of transmission are not well
defined because most care-givers who have acquired infec-
tion have had multiple contacts by multiple modes.8,15 In this
study, we aim to describe the transmission of the CCHFV
infection to HCWs in a hospital where a significant number
of CCHF patients had been cared for.Published by Elsevier Ltd. All rights reserved.
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Table 1 Demographic characteristics of HCWs at risk and
not at risk for CCHFV infection
HCWs at
risk no. (%)
HCWs not at
risk no. (%)
Number of HCWs 62 13
Median age  standard
deviation
33  8 34  9
Female 40 (65) 11 (85)
Profession
Nurse 23 (37) 7 (54)
Resident 11 (18) 4 (31)
Housekeeping staff 15 (24) — (0)
Specialist 7 (11) 1 (8)
Laboratory
technician
6 (10) 1 (8)
Department
Infectious
diseases ward
24 (39) 2 (15)
Emergency 20 (32) 2 (15)
Laboratory 6 (10) 5 (39)
Hematology 7 (11) — (0)
General surgery 4 (6) 1 (8)
Dermatology — (0) 2 (15)
Other 1 (2) 1 (8)
Tick bite — (0) — (0)
Travel to
endemic region
5 (8) — (0)
CCFHV: Crimean-Congo hemorrhagic fever virus; HCW: health-
care worker.Methods
The study was conducted in Ankara Numune Education and
Research Hospital, which is one of the largest referral ter-
tiary-care community hospitals in Turkey. Nearly 100 patients
who had positive IgM or PCR results for CCHFV and who
were confirmed to have had CCHFV infection, were followed
up in the clinics of our hospital.
The study group included two main subgroups of HCWs:
(1) HCWs at risk — those who worked in the units where the
care of CCHF patients took place. These units were the
infectious diseases clinic, emergency department, hema-
tology clinic, laboratory units, and surgery team. A propor-
tion of this group performed jobs with higher risk of
exposure, such as examination of bleeding patients, phle-
botomy, cleaning of blood or body fluids from the patients,
and performing medical and surgical interventions. (2)
HCWs not at risk — the control group, free from contact
with any symptomatic patient with CCHF. No CCHF con-
firmed or suspected patients had been admitted to their
wards. All the HCWs who were at risk were targeted for
inclusion in the study. Two infectious diseases physicians
(OE and AC) administered a structured questionnaire
in person to collect data on demographics, occupation,
department, use of personal protective equipment (gloves,
gown, and mask), and exposure to the body fluids of
patients. Informed individual consent was obtained from
the HCWs participating in the study.
The sera from the HCWs were collected one month after
the last admitted hospital case (October 2003), and were
studied for specific CCHF IgM and IgG antibodies by ELISA at
the Pasteur Institute, Lyon, France.
Data were analyzed using Stata Statistical Software, ver-
sion 8.0 (Stata Corp., Texas, USA). Mean comparisons for
continuous variables were done using independent group
t tests. Proportion comparisons for categorical variables
were done using Chi-square tests, although Fisher’s exact
test was used when data were sparse.
Results
Seventy-five HCWs were included in the study; the
median age was 30 and 68% of the subjects were female.
All the nurses and 70% of the residents and specialists at
risk were included in the study. The study group included
62 HCWs who were at risk of exposure to the body fluids
of patients and 13 HCWs with no risk. Both groups were
similar in terms of age ( p = 0.708) and gender ( p = 0.203)
(Table 1).
Sixty-two HCWs performed jobs with higher risk of expo-
sure, such as examination of bleeding patients, phlebotomy,
cleaning of blood or body fluids from the patients, and
performing medical and surgical interventions. No needle-
stick injury contaminated with CCHFV blood or body fluids, or
any other exposure was reported. More than 80% of the HCWs
who were at risk, adhered to the use of gloves and 11% used
masks. The floors of the wards and the patients’ rooms were
disinfected with hypochlorite solutions rigorously and the
housekeeping personnel were warned about the risk of trans-
mission. None of the HCWs was CCHF IgM positive, and only
one nurse was CCHF IgG positive, even though she was not atrisk. One of the CCHF confirmed patients had undergone
surgery, and none of the operation team members became
seropositive.
Discussion
CCHF is a viral hemorrhagic syndrome presenting with
fever, nausea, vomiting, myalgia, and bleeding from
various organs. Reports from Turkey on the syndrome
were first published in 2004.16,17 Nearly 100 confirmed
CCHF patients in the hospital were admitted in the
spring and summer months of 2002 and 2003. Seventy-
five percent of the patients were admitted before
mid-August 2003, when the disease was not yet recog-
nized.16 The mean length of hospital stay of the patients
was 11 days.
The hospital HCWs were at serious risk of transmission of
the infection, particularly during patient follow-up when
hemorrhages from the nose, mouth, gums, vagina, and
injection sites can occur. The transmission of CCHFV and
resultant death among HCWs has been reported since
1976.14 It has previously been reported that 8.7% of HCWs
who had been exposed to infected blood, and 33% of HCWs
who had had a needlestick injury developed the disease.10
The individual in our study with the positive CCHF IgG
antibody level was not at risk and she had no history of tick
50 O. Ergonul et al.bite; she did, however, report that she had been in an
endemic region eight years previously.
The most important risk factors for transmission of infec-
tion have been reported to be intervention in gastrointes-
tinal bleeding and operations in an emergency without
knowing the patient’s diagnosis.14 In general, patients have
been diagnosed after operation, and injuries during opera-
tion have usually been underreported. One of the patients in
a previously reported study at this hospital was operated
on because of atypical presentation of acute appendicitis.18
All of the operation team members were studied for CCHFV
infection and none of them had clinical signs or symptoms
of the infection. This lack of infection is probably related to
two factors; firstly, before the operation the team members
were warned of the potential presence of a viral hemorrhagic
fever infection such as Ebola, and secondly the patient was
on day eight of ribavirin therapy.
Epidemiological studies of viral hemorrhagic fevers
(VHF) indicate that infection is not readily transmitted
from person to person by airborne routes,7,15 and our study
supports this. In our study the rate of mask use was low
(11%) among the at-risk HCWs. The guidelines for the
management of viral hemorrhagic fever published by CDC
in 1988,19 and updated in 19956 recommend caution with
body fluids such as excreta, vomit, sweat, and saliva,
especially from patients with respiratory symptoms or in
the later stages of the illness characterized by vomiting,
diarrhea, hemorrhage, and shock.6,19 The recommended
safety measures include barrier nursing and isolation, and
the use of gloves, gowns, face-shields, and goggles with
side shields when coming into contact with the patient or
soiled environmental surfaces.
In our study, the healthcare workers were at the time
(2002/2003) so unfamiliar with these first cases of CCHFV
infection, that some of the patients were misdiagnosed as
having febrile neutropenia. Since the cause of infection was
not known until August 2003, the protective measures used
were limited to simple general precautions, such as using
gloves during phlebotomy, and self-protection from every
kind of bodily fluid from the patients by the use of masks
and gowns. Simple barrier precautions have been reported
to be effective when rigorously applied.18,20,21 Our results
support these reports. In a prospective serological study
from Sierra Leone it was suggested that the hospital staff
who care for Lassa fever patients using simple barrier
nursing methods, have no higher risk of infection than
the local population.22 In our study, we do not have data
from the community to compare with the hospital workers.
In other recent studies, prophylactic ribavirin was adminis-
tered to HCWs who had been exposed to the infection.3,12
We suggest rigorous daily follow-up by checking complete
blood count, and biochemical tests for the exposed indivi-
duals. Ribavirin prophylaxis should be recommended for
HCWs who are at high risk of exposures such as percuta-
neous injuries.
Conclusions
There was no serologic evidence of healthcare-related
CCHFV transmission in the recent outbreak in Turkey. This
result could be related to the high rate of compliance touniversal precautions, which seem to have been sufficient to
give protection against CCHFV infection.
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